Evidence map›Paper›PMID 31194608›Full record

ArticleJournal of global oncology2019

Collaborative Molecular Epidemiology Study of Metabolic Dysregulation, DNA Methylation, and Breast Cancer Risk Among Nigerian Women: MEND Study Objectives and Design.

Tomi Akinyemiju, Omolola Salako, Adetola Daramola, Olusegun Alatise, Adewale Adeniyi, Gabriel Ogun, Omobolaji Ayandipo, Thomas Olajide, Olalekan Olasehinde, Olukayode Arowolo and 7 more

Open access · goldAbstract read
In one paragraph

Article in Journal of global oncology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.6field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 8 institutions in 2 countries.

Tomi AkinyemijuUniversity of Kentucky, Lexington, KY.
Omolola SalakoLagos University Teaching Hospital, Lagos, Nigeria.
Adetola DaramolaLagos University Teaching Hospital, Lagos, Nigeria.
Olusegun AlatiseObafemi Awolowo University Teaching Hospital, Ile-Ife, Nigeria.
Adewale AdeniyiFederal Medical Center, Abeokuta, Nigeria.
Gabriel OgunUniversity of Ibadan, Ibadan, Nigeria.
Omobolaji AyandipoUniversity of Ibadan, Ibadan, Nigeria.
Thomas OlajideLagos University Teaching Hospital, Lagos, Nigeria.
Olalekan OlasehindeObafemi Awolowo University Teaching Hospital, Ile-Ife, Nigeria.
Olukayode ArowoloObafemi Awolowo University Teaching Hospital, Ile-Ife, Nigeria.
Adewale AdisaObafemi Awolowo University Teaching Hospital, Ile-Ife, Nigeria.
Oludolapo AfuwapeUniversity of Ibadan, Ibadan, Nigeria.
Aralola OlusanyaUniversity of Ibadan, Ibadan, Nigeria.
Aderemi AdegokeOur Lady of Apostle Catholic Hospital, Ibadan, Nigeria.
Akinlolu OjoUniversity of Arizona, Tucson, AZ.
Trygve TollefsbolUniversity of Alabama at Birmingham, Birmingham, AL.
Donna ArnettUniversity of Kentucky, Lexington, KY.
University of Ibadan · NGLagos University Teaching Hospital · NGEkiti State University · NGUniversity of Kentucky · USAdekunle Ajasin University · NGObafemi Awolowo University · NGUniversity of Alabama at Birmingham · USUniversity of Arizona · US

Funding

XRAY CRYSTALLOGRAPHYP30CA013148 · NCI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI Robert S Welner · 1985 to 2026
$165.9M
University of Alabama at Birmingham's Diabetes Research CenterP30DK079626 · NIDDK · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI Kirk Michael Habegger · 2013 to 2026
$19.5M
Combinatorial epigenetic-based prevention of breast cancerR01CA178441 · NCI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI TOLLEFSBOL, TRYGVE O · 2014 to 2025
$3.2M
Early life prevention of breast cancer with combined epigenetic botanicalsR01CA204346 · NCI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI TOLLEFSBOL, TRYGVE O · 2017 to 2021
$1.7M
Metabolic Syndrome and Epigenetic Markers of Breast Cancer in Nigerian WomenK01TW010271 · FIC · UNIVERSITY OF KENTUCKY · PI AKINYEMIJU, TOMI F · 2016 to 2020
$676k
FIC NIH HHS K01 TW010271NCI NIH HHS P30 CA013148NCI NIH HHS R01 CA178441NCI NIH HHS R01 CA204346NIDDK NIH HHS P30 DK079626
6 · The paper itself

Abstract

purposeTo elucidate the role of metabolic dysregulation and associated DNA methylation changes on breast cancer risk and aggressive subtypes among Nigerian women. We describe the design and methods of a collaborative molecular epidemiology study of breast cancer in Nigerian hospitals.

methodsThe Mechanisms for Novel and Established Risk Factors for Breast Cancer in Women of Nigerian Descent (MEND) study was designed as a matched case-control study of 350 patients, age 18 to 75 years, with newly diagnosed, treatment-naïve breast cancer and 350 age-matched healthy controls from surrounding geographic areas. Patients with breast cancer seen for initial diagnosis at four large tertiary hospitals in southwest Nigeria and one affiliated private hospital were recruited. Healthy female controls were selected from a cohort of 4,000 healthy women recruited as part of the Human Heredity and Health (H3) in Africa Chronic Kidney Disease Case-Control Study in Nigeria. Tumor and adjacent normal tissue, and blood and saliva samples were collected for molecular and epigenetic assays.

resultsAlthough recruitment is ongoing, a total of 416 patients have been recruited to date, with tumor and blood samples obtained from at least 310 patients. Data on age-matched (± 6 months) controls have also been obtained and harmonized. Lipid assays for 350 pathologically verified cases and 350 age-matched controls is underway, and pathologic characterization of tumors (including immunohistochemistry for subtyping) is ongoing. Data on DNA methylation for tumors and adjacent normal tissue are expected by the end of the study period.

conclusionThe MEND study will provide a unique, high-quality source of data to evaluate the contribution of metabolic dysregulation such as obesity, diabetes, hypertension, and metabolic syndrome to the biology of breast cancer among Nigerian women and foster collaborative studies relevant for women of African descent globally.

Indexed as

DNA MethylationAdolescentAdultAgedBreast NeoplasmsCase-Control StudiesFemaleHumansMedical RecordsMetabolic DiseasesMiddle AgedMolecular EpidemiologyNigeriaResearch DesignRisk FactorsYoung Adult

Identifiers

PMID31194608
PMCPMC6613666
OpenAlexW2950129792

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.